Clinical evaluation of the effectiveness of a new fixed combination antihypertensive drug based on brimonidine and brinzolamide in primary open-angle glaucoma
DOI:
https://doi.org/10.31288/oftalmolzh202441017Keywords:
primary open-angle glaucoma, fixed combination antihypertensive drugsAbstract
Introduction. Combined drug treatment of primary open-angle glaucoma (POAG) with several types of antihypertensive drops from different pharmacological groups is performed to enhance the hypotensive effect in cases when monotherapy does not always reduce intraocular pressure (IOP) to a tolerance level.
Рurpose. Evaluation of the effectiveness and tolerability of a fixed combination antihypertensive drug, Glaubrinza, in the treatment of patients with POAG.
Methods. Depending on the treatment, 2 groups of patients were formed. The main group included 30 patients (60 eyes), who instilled the drug Glaubrinza, 1 drop 2 times a day. The comparison group consisted of 30 patients (60 eyes), whom the drug Simbrinza was instilled according to the same scheme as the drug Glaubrinza.
All patients underwent a general ophthalmological examination and special research methods, including: computer static perimetry, pachymetry, and optical coherence tomography (OCT). The local and general tolerability of the drug was assessed within 10 days using a standard scale.
Results. The effectiveness of the treatment in the main group was assessed as high in 85% and moderately high in 15% and averaged 3.8±0.1 points. The effectiveness of treatment in the comparison group was assessed as moderately high in 20% and high in 80% of patients and averaged 3.8±0.03 points.
Conclusions. Glaubrinza is a highly effective drug for treating POAG and is not inferior in all studied parameters to the reference drug and is also economically accessible to all segments of the population.
References
Abe RY, Diniz-Filho A, Costa VP, Gracitelli CP, Baig S, Medeiros FA. The impact of location of progressive visual field loss on longitudinal changes in quality of life of patients with glaucoma. Ophthalmology 2016;123(3):552-557. https://doi.org/10.1016/j.ophtha.2015.10.046
Abe RY, Gracitelli CP, Diniz-Filho A, Zangwill LM, Weinreb RN, Medeiros FA. Frequency doubling technology perimetry and changes in quality of life of glaucoma patients: A longitudinal study. Am J Ophthalmol 2015;160(1):114-122.e111. https://doi.org/10.1016/j.ajo.2015.04.007
Bakhritdinova FA et al. Assessment of the quality of life of patients with primary open-angle glaucoma in the process of drug treatment treatment. Adv. Ophthalmol. 2023;1(1):24-27.
Bakhritdinova FA, Karimov UR, Mirrakhmova SSh, Comparison of fixed topical combination glaucoma drugs in patients with open-angle glaucomsa or ocular hypertension. European science review. 2016; 3-4:113-118. https://doi.org/10.20534/ESR-16-3.4-113-118
Bakhritdinova FA, Bilalov EN, Narzikulova KI, Egamberdieva ME, Oralov BA. Assessing the quality of life of patients during conservative and surgical treatment of primary open-angle glaucoma IOK Uzbekistan 2023. Biology va Tibbiyot Muammolari. 2024; №3 (154): 29-36.
Bakhritdinova FA, Narzikulova KI, Egamberdieva ME, Boboev SA. Review of fixed combinations in the treatment of primary open-angle glaucoma Biology va Tibbiyot Muammolari. 2023; 5(148): 349-355.
Cavet ME, De Cory OHT. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1-2):52-60. https://doi.org/10.1089/jop.2016.0188
Fan S, Agrawal A, Gulati V, et al. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension. J Glaucoma. 2014;23: 276e281. https://doi.org/10.1097/IJG.0000000000000051
Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31:1213-1227 https://doi.org/10.1007/s12325-014-0168-y
Hoy SM. Latanoprostene Bunod ophthalmic solution 0.024%: A review in open-angle glaucoma and ocular hypertension. Drugs. 2018;78(7):773-780. https://doi.org/10.1007/s40265-018-0914-6
Kamaruddin MI, Nakamura-Shibasaki M, Mizuno Y, Kiuchi Y. Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits. Clinical Ophthalmology. 2017;11:591-597. https://doi.org/10.2147/OPTH.S131416
Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86-93. https://doi.org/10.1136/bjophthalmol-2015-307223
Kóthy P, Holló G. Practical experience with the use of a combination of brinzolamide/brimonidine fixed drops in the center of tertiary glaucoma. Int ophthalmol. 2020; 40: 377-383. https://doi.org/10.1007/s10792-019-01194-6
Knight LSW, Ruddle JB, Taranath DA, Goldberg I, Smith JEH, Gole G, et al. Childhood and Early Onset Glaucoma Classification and Genetic Profile in a Large Australasian Disease Registry. Ophthalmology. 2021 Nov;128(11):1549-1560. https://doi.org/10.1016/j.ophtha.2021.04.016
Quaranta L, Riva I, Gerardi Ch, Oddone F, Floriano I, Konstas AGP. Quality of Life in Glaucoma: A Review of the Literature Adv Ther. 2016; 33(6): 959-981 https://doi.org/10.1007/s12325-016-0333-6
Li G, Torrejon KY, Unser AM. et al. Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice. IOVS. 2018;59(1):383. https://doi.org/10.1167/iovs.17-23212
Liu JH, Slight JR, Vittitow JL, et al. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. 2016;169:249e257. https://doi.org/10.1016/j.ajo.2016.04.019
Machen L, Razeghinejad R, Myers JS. Fixed-combination topical anti-hypertensive ophthalmic agents. Expert Opin Pharmacother. 2020;1-14. https://doi.org/10.1080/14656566.2020.1743264
Moosavi R, Ansari E. Brinzolamide/brimonidine fixed combination: simplifying glaucoma treatment regimens. Ophthalmol Ther. 2018;7(2):397-403. https://doi.org/10.1007/s40123-018-0150-x
Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2015; 112:953-961. https://doi.org/10.1016/j.ophtha.2004.12.035
Ozcura F, Yildirim N, Tambova E, Sahin A. Evaluation of Goldmann applanation tonometry, rebound tonometry and dynamic contour tonometry in keratoconus. J Optom. 2017;10(2):117-122. https://doi.org/10.1016/j.optom.2016.04.005
Okafor KC, Brandt JD. Measuring intraocular pressure. Current opinion in ophthalmology. 2015;26(2):103-109. https://doi.org/10.1097/ICU.0000000000000129
Weinreb RN, Bacharach J, Fechtner RD, Kahook MY, Wirta D, Burmaster S, et al. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1% / Brimonidine 0.2%: A Multicenter, Randomized Trial. Ophthalmology. 2019 Aug;126(8):1095-1104. https://doi.org/10.1016/j.ophtha.2018.10.040
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-540. https://doi.org/10.1016/j.ajo.2007.06.012
Rossi GC, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23: 296-302. https://doi.org/10.5301/ejo.5000220
Rykov S., Mogilevskyy S., Petrenko O., Denisyuk L., Medvedovska N., Korytnyuk R. New possibilities of conservative treatment of primary open-angle glaucoma. Bulletin of Problems of Biology and Medicine. 2018; 1, 2 (143). https://doi.org/10.29254/2077-4214-2018-1-2-143-184-188
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1-9.e2. https://doi.org/10.1016/j.ajo.2011.05.033
Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye (Lond). 2009;23(1):132-140. https://doi.org/10.1038/sj.eye.6702964
Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-34. https://doi.org/10.1111/aos.12829
Yadav KS, Rajpurohit R, Glaucoma: SS. Current treatment and impact of advanced drug delivery systems. Life Sci. 2019. https://doi.org/10.1016/j.lfs.2019.02.029
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bakhritdinova F., Narzikulova K., Mirrakhimova S., Egamberdiyeva M., Nazirova S.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
